Toronto - Delayed Quote ? CAD BriaCell Therapeutics Corp. (BCT.TO) Follow Compare 1.1600 0.0000 (0.00%) At close: October 18 at 3:59 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT? combination with immune check point inhibitor in metastatic breast cancer (MBC)Primary endpoint is overall survival (OS) with Bria-IMT? regimen plus Check Point Inhibitor (CPI) vs treatment of physician’s choiceInterim data analysis planned at 144 events (deaths) could provide full approval and marketing authorizationPivotal Phase 3 study patient enrollment completion is expected in mid-2025 No serious adverse events related to GlobeNewswire ? 4 days ago BCTX BCTXW BriaCell Therapeutics Announces Closing of $5 Million Offering PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated war GlobeNewswire ? 17 days ago BCTX BCTXW BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq RulesPHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share an GlobeNewswire ? 18 days ago BCTX BCTXW BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with “Eye-Bulging” metastatic breast cancerHeavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC) therapy and continues to receive BriaCell treatment PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo GlobeNewswire ? 18 days ago BCTX BCTXW What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Zacks ? 22 days ago BCTXW BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT? to those cancer patients in need beyond the scope of BriaCell’s pivotal Phase 3 clinical trial. PHILADELPHIA and VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company tha GlobeNewswire ? last month BCTX BCTXW BriaCell Therapeutics Announces Closing of $8.5 Million Offering PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering priced at-the-market under Nasdaq rules for 12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross GlobeNewswire ? last month BCTX BCTXW BriaCell Therapeutics Announces US$8.5 Million Share Offering BriaCell Therapeutics Announces US$8.5 Million Share Offering PREMIUM MT Newswires ? last month BCTXW BriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq RulesPHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 12,325,000 common shares (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), priced at-the-market under Nasdaq rule GlobeNewswire ? last month BCTX BCTXW Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday On Wednesday, BriaCell Therapeutics (NASDAQ:BCTX) stock traded higher with a session volume of 113.08 million, compared to the average volume of 366.19 thousand, according to data from Benzinga Pro. BriaCell Therapeutics announced overall survival data from its Phase 2 clinical study of Bria-IMT in combination with an immune checkpoint inhibitor (CPI) in late-stage metastatic breast cancer. The company reported a median overall survival of 15.6 months from its most recent patients (treated since Benzinga ? last month BCTXW BriaCell Reports Longer Overall Survival Rate in Phase 2 Breast Cancer Study BriaCell Reports Longer Overall Survival Rate in Phase 2 Breast Cancer Study PREMIUM MT Newswires ? last month BCTXW BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer Median overall survival of 15.6 months in Phase 2 Bria-IMT? study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literatureOngoing Phase 3 study investigating Bria-IMT? in similar metastatic breast cancer populationNo drug related discontinuations to date PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (T GlobeNewswire ? last month BCTX BCTXW BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+? for Prostate Cancer BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+? in prostate cancerThe meeting provides a clear path towards filing an IND and conducting a Phase 1/2 study of Bria-PROS+? PHILADELPHIA and VANCOUVER, British Columbia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapi GlobeNewswire ? last month BCTX BCTXW BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX. “We are thrilled to be invited to present our data at this prestigious conference GlobeNewswire ? last month BCTX BCTXW BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously reportedHeavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC) therapy and continues to receive BriaCell treatment PHILADELPHIA and VANCOUVER, British Columbia, July 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX GlobeNewswire ? 3 months ago BCTX BCTXW BriaCell Presents Clinical Efficacy Data at ASCO 2024 BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT? PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patientsTherapy well-tolerated with no Bria-IMT? related discontinuationsClinical data highlight significant potential of Bria-IMT? in advanced metastatic breast cancerSuperiority of selected Phase 3 regimen and formulation confirmedOral presentation by Mayo Clinic Profe GlobeNewswire ? 4 months ago BCTX BCTXW BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS? in Advanced Metastatic Breast Cancer PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS?, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor ti GlobeNewswire ? 4 months ago BCTX BCTXW BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study PREMIUM MT Newswires ? 4 months ago BCTXW BGNE BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024 83% intracranial objective response rate (iORR) with Bria-IMT? in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studies1,2,3 PHILADELPHIA and VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics C GlobeNewswire ? 4 months ago BCTX BCTXW This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year Looking at BriaCell Therapeutics Corp.'s ( TSE:BCT ) insider transactions over the last year, we can see that insiders... Simply Wall St. ? 4 months ago BCTX BCTXW Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return BCT.TO S&P/TSX Composite index YTD -85.13% +18.44% 1-Year -84.86% +26.05% 3-Year -88.53% +18.61%
